Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Latest Information Update: 30 May 2024
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cobolimab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
- Indications Cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms IOLite
- Sponsors GlaxoSmithKline; GSK; TESARO
- 27 May 2024 Planned End Date changed from 22 Apr 2024 to 30 Aug 2024.
- 02 Jun 2023 Planned End Date changed from 20 Apr 2023 to 22 Apr 2024.
- 31 Oct 2022 Planned End Date changed from 31 Oct 2022 to 20 Apr 2023.